{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:13Z","timestamp":1790963593981,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009210","name":"Taiwan FDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["111-2314-B-038-074 -"],"award-info":[{"award-number":["111-2314-B-038-074 -"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["111-2314-B-038-139-"],"award-info":[{"award-number":["111-2314-B-038-139-"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejphar.2023.175526","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T10:47:18Z","timestamp":1674298038000},"page":"175526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma"],"prefix":"10.1016","volume":"943","author":[{"given":"Syahru Agung","family":"Setiawan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston Zhenhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei\u2010Wei","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hwa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijesh Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardiah Suci","family":"Hardianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5189-9755","authenticated-orcid":false,"given":"Chi-Tai","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Yi","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.175526_bib1","doi-asserted-by":"crossref","first-page":"F702","DOI":"10.1152\/ajprenal.00044.2017","article-title":"Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells","volume":"314","author":"Adedoyin","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2023.175526_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1590\/1414-431X20143437","article-title":"Trypan blue exclusion assay by flow cytometry","volume":"47","author":"Avelar-Freitas","year":"2014","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.ejphar.2023.175526_bib3","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-120761","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"132","author":"Blombery","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.175526_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","article-title":"Targeting BTK in CLL: beyond ibrutinib","volume":"14","author":"Bond","year":"2019","journal-title":"Curr. Hematol. Malignancy Rep."},{"key":"10.1016\/j.ejphar.2023.175526_bib5","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2023.175526_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hon.2581","article-title":"Double-hit lymphoma: so what?","volume":"37","author":"Davies","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2023.175526_bib7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2015.12.001","article-title":"Diffuse large B-cell lymphoma with MYC gene rearrangements: current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature","volume":"55","author":"de Jonge","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2023.175526_bib8","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2023.175526_bib9","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/0008-5472.CAN-21-0218","article-title":"Targeting cellular iron homeostasis with ironomycin in diffuse large B-cell lymphoma","volume":"82","author":"Devin","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2023.175526_bib10","first-page":"357","article-title":"Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia","author":"Fischer","year":"2020","journal-title":"Hematol. 2020"},{"key":"10.1016\/j.ejphar.2023.175526_bib11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2017-04-737320","article-title":"How I treat double-hit lymphoma","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.175526_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-020-00914-1","article-title":"Emerging therapies in mantle cell lymphoma","volume":"13","author":"Hanel","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2023.175526_bib13","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.175526_bib14","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2023.175526_bib15","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.175526_bib16","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejphar.2023.175526_bib17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41374-017-0008-1","article-title":"Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma","volume":"98","author":"Kinowaki","year":"2018","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ejphar.2023.175526_bib18","doi-asserted-by":"crossref","first-page":"P17","DOI":"10.1186\/1758-2946-4-S1-P17","article-title":"Mcule.com: a public web service for drug discovery","volume":"4","author":"Kiss","year":"2012","journal-title":"J. Cheminf."},{"key":"10.1016\/j.ejphar.2023.175526_bib19","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-16-0555","article-title":"Combination of ibrutinib and ABT-199 in diffuse large B-cell lymphoma and follicular lymphoma","volume":"16","author":"Kuo","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2023.175526_bib20","doi-asserted-by":"crossref","first-page":"24393","DOI":"10.18632\/oncotarget.5162","article-title":"Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death","volume":"6","author":"Kwon","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2023.175526_bib21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12308-020-00404-w","article-title":"A practical approach to FISH testing for MYC rearrangements and brief review of MYC in aggressive B-cell lymphomas","volume":"13","author":"Larson","year":"2020","journal-title":"J. Hematopathol."},{"key":"10.1016\/j.ejphar.2023.175526_bib22","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.175526_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1158\/1535-7163.MCT-18-0478","article-title":"Pleiotropic action of novel Bruton's tyrosine kinase inhibitor BGB-3111 in mantle cell lymphoma","volume":"18","author":"Li","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2023.175526_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7559","article-title":"MYC\/BCL2\/BCL6 triple hit lymphoma: a study of 33 patients who had an aggressive clinical course similar to patients with double hit lymphomas","volume":"35","author":"Li","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2023.175526_bib25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-019-0761-2","article-title":"Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with epigenetic bromodomain inhibitors","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2023.175526_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-021-00429-z","article-title":"Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication","volume":"11","author":"Lu","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejphar.2023.175526_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-019-00635-7","article-title":"Inhibiting Bruton's tyrosine kinase in CLL and other B-cell malignancies","volume":"14","author":"Lucas","year":"2019","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.ejphar.2023.175526_bib28","doi-asserted-by":"crossref","first-page":"29753","DOI":"10.18632\/oncotarget.25707","article-title":"MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways","volume":"9","author":"Malpeli","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2023.175526_bib29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.2695","article-title":"Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on","volume":"38","author":"Molica","year":"2020","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2023.175526_bib30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2016-05-718494","article-title":"Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling","volume":"129","author":"Myklebust","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.175526_bib31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2023.175526_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/08998280.2014.11929083","article-title":"Triple-hit lymphoma","volume":"27","author":"Pemmaraju","year":"2014","journal-title":"Baylor Univ. Med. Center Proc."},{"key":"10.1016\/j.ejphar.2023.175526_bib33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3390\/ijms19020448","article-title":"Apoptosis: a target for anticancer therapy","volume":"19","author":"Pfeffer","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2023.175526_bib34","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","article-title":"Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas","volume":"24","author":"Pham","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2023.175526_bib35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.2019000854","article-title":"Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study","volume":"134","author":"Quinquenel","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.175526_bib36","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41556-020-0532-x","article-title":"Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels","volume":"22","author":"Roider","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejphar.2023.175526_bib37","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the lunenburg lymphoma biomarker consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2023.175526_bib38","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/1535-7163.MCT-19-0273","article-title":"Expression levels of therapeutic targets as indicators of sensitivity to targeted therapeutics","volume":"18","author":"Roy","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2023.175526_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/PPO.0000000000000408","article-title":"BCL-2 inhibitors, present and future","volume":"25","author":"Ryan","year":"2019","journal-title":"Cancer J."},{"key":"10.1016\/j.ejphar.2023.175526_bib40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13073-015-0187-6","article-title":"Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas","volume":"7","author":"Sha","year":"2015","journal-title":"Genome Med."},{"key":"10.1016\/j.ejphar.2023.175526_bib41","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2643-3230.BCD-21-0063","article-title":"Overcoming acquired epigenetic resistance to BTK inhibitors","volume":"2","author":"Shaffer","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ejphar.2023.175526_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00354","article-title":"The senolytic drug navitoclax (ABT-263) causes trabecular bone loss and impaired osteoprogenitor function in aged mice","volume":"8","author":"Sharma","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejphar.2023.175526_bib43","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3324\/haematol.2013.091827","article-title":"Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma","volume":"99","author":"Sietse","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ejphar.2023.175526_bib44","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1021\/ja411006a","article-title":"Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models","volume":"136","author":"Skouta","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejphar.2023.175526_bib45","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.3324\/haematol.2021.278654","article-title":"Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ejphar.2023.175526_bib46","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3390\/cancers13071620","article-title":"High-grade B-cell lymphoma (HGBL) with MYC and BCL2 and\/or BCL6 rearrangements is predominantly BCL6-rearranged and BCL6-expressing in Taiwan","volume":"13","author":"Tsai","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2023.175526_bib47","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-2141.2006.06468.x","article-title":"Bruton's tyrosine kinase prevents activation of the anti-apoptotic transcription factor STAT3 and promotes apoptosis in neoplastic B-cells and B-cell precursors exposed to oxidative stress","volume":"136","author":"Uckun","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejphar.2023.175526_bib48","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3324\/haematol.2019.220525","article-title":"Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma","volume":"105","author":"Victoria","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ejphar.2023.175526_bib49","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1159\/000505892","article-title":"The spectrum of MYC alterations in diffuse large B-cell lymphoma","volume":"143","author":"Xia","year":"2020","journal-title":"Acta Haematol."},{"key":"10.1016\/j.ejphar.2023.175526_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8457521","article-title":"Ferroptosis: a new promising target for lung cancer therapy","author":"Xiong","year":"2021","journal-title":"Oxid. Med. Cell. Longev. 2021"},{"key":"10.1016\/j.ejphar.2023.175526_bib51","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12935-020-01518-y","article-title":"Ibrutinib in B-cell lymphoma: single fighter might be enough?","volume":"20","author":"Xue","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejphar.2023.175526_bib52","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ejphar.2023.175526_bib53","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1182\/bloodadvances.2020003698","article-title":"Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma","volume":"6","author":"Yang","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejphar.2023.175526_bib54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2023.175526_bib55","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/imr.12792","article-title":"Pathogenic B-cell receptor signaling in lymphoid malignancies: new insights to improve treatment","volume":"291","author":"Young","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejphar.2023.175526_bib56","article-title":"FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations","author":"Zhou","year":"2020","journal-title":"Database 2020"},{"key":"10.1016\/j.ejphar.2023.175526_bib57","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00277-021-04535-7","article-title":"Ibrutinib combined with venetoclax for the treatment of relapsed\/refractory diffuse large B cell lymphoma","volume":"100","author":"Zhou","year":"2021","journal-title":"Ann. Hematol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923000377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923000377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:21:00Z","timestamp":1762143660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923000377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":57,"alternative-id":["S0014299923000377"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175526","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175526"}}